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The genes encoding Caspase-9 and DFF45 have both recently been mapped to chromosome region 1p36.2, that is a region
alleged to involve one or several tumour suppressor genes in neuroblastoma tumours. This study presents an update contig of
the ‘Smallest Region of Overlap of deletions’ in Scandinavian neuroblastoma tumours and suggests that DFF45 is localized in
the region. The genomic organization of the human DFF45 gene, deduced by in-silico comparisons of DNA sequences, is
described for the ﬁrst time in this paper. In the present study 44 primary tumours were screened for mutation by analysis of
the genomic sequences of the genes. In two out of the 44 tumours this detected in the DFFA gene one rare allele variant that
caused a non-polar to a polar amino acid exchange in a preserved hydrophobic patch of DFF45. One case was hemizygous
due to deletion of the more common allele of this polymorphism. Out of 194 normal control alleles only one was found to
carry this variant allele, so in respect of it, no healthy control individual out of 97 was homozygous. Moreover, our RT–PCR
expression studies showed that DFF45 is preferably expressed in low-stage neuroblastoma tumours and to a lesser degree in
high-stage neuroblastomas. We conclude that although coding mutations of Caspase-9 and DFF45 are infrequent in
neuroblastoma tumours, our discovery of a rare allele in two neuroblastoma cases should be taken to warrant further studies
of the role of DFF45 in neuroblastoma genetics.
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Neuroblastoma, a paediatric tumour originating in the neural crest
cells, is a heterogeneous disease with tumour progression or spon-
taneous regression dependent on anatomic stage and age at
diagnosis. Of a group of chromosomal aberrations proven to corre-
late with the prognosis of neuroblastoma, the most common are
deletion in the short arm of 1p (1p36.2-3) and ampliﬁcation of
the proto-oncogene MYCN on 2p24.1 (reviewed in Brodeur,
1990). More recently, gain of parts of the long arm of chromosome
17 (17q gain) has also been shown to have prognostic value (Abel
et al, 1999; Bown et al, 1999).
Apoptosis or programmed cell death (PCD) is responsible for
the maintenance of homeostasis in tissues as well as in embryonic
development. Called caspases; the key apoptotic effectors comprise
a family of cysteine proteases that requires cleavage after a speciﬁc
internal Asp residue for activation (Li et al, 1997; Srinivasula et al,
1998). Caspase-9, a 45-kDa protein (also called ‘Apoptotic protease
activating factor-3’, Apaf-3, ICE-LAP-6, Mch6), has been shown to
be a critical and furthest upstream member of the mitochondrial-
mediated apoptotic protease cascade (Li et al, 1997; Kuida et al,
1998; Srinivasula et al, 1998). Activated by Apaf-1-mediated oligo-
merization, Procaspase-9 in turn activates by proteolytic cleavage
downstream caspases such as caspase-3, -6 and -7 (Li et al, 1997;
Srinivasula et al, 1998). Caspase-3 in turn cleaves a selected group
of substrates that cause the morphological and biochemical changes
that characterize apoptotic cell death. One of the caspase-3 down-
stream substrate proteins is DFF (DNA Fragmentation Factor; Liu
et al, 1997; Enari et al, 1998; Halenbeck et al, 1998); it is a hetero-
dimeric protein composed of one 40- and one 45-kDa subunit (Liu
et al, 1997). DFF40 (synonymous names CPAN ‘Caspase-Activated
Nuclease’/CAD ‘Caspase-Activated Dnase’) is a DNase that triggers
both DNA fragmentation and chromatin condensation (Liu et al,
1998). DFF45 (also called ICAD ‘Inhibition of CAD’) is an inhibi-
tor of DFF40, that also functions as a chaperone for native DFF40
(Gu et al, 1999; Sakahira et al, 2000).
Dysregulation of apoptosis is likely to be instrumental in the devel-
opment and/or progression of childhood tumour neuroblastoma.
Apoptotic factors correlate in several respects with prognosis of
neuroblastoma. Bcl-2, an apoptotic repressor located as a transmem-
brane protein in the mitochondria, endoplasmatic reticulum and
nuclei, has been reported to provide prognostic information in some
neuroblastoma (Ikeda et al, 1995; Mejia et al, 1998). Moreover, Ikeda
et al (1997) reported that caspase-1 is preferentially expressed in
neuroblastoma with favourable prognosis. Also, Caspase-8 is poorly
expressed in neuroblastoma tumours due to deletion or inactivation
by methylation (Teitz et al, 2000). Recently, structure and mutation
analysis of the gene encoding DFF40, DFFB, was performed in
primary neuroblastoma tumours and cell-lines (Judson et al, 2000).
However, DFFB could not be shown to be imprinted or to contain
any somatic mutations in tumour samples. Gene-targeting studies
of CASP9 have shown that it is important during brain development.
A majority of CASP9 knockout mice has been shown to die perina-
tally with a markedly enlarged and malformed cerebrum caused by
reduced apoptosis (Hakem et al, 1998; Kuida et al, 1998). No
DFF45/ICAD-deﬁcient mouse has shown any developmental
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tation and DNA condensation and are partially resistant to undergo
apoptosis (Zhang et al, 1998, 1999).
Both the CASP9 (OMIM number 602234) and the DFFA (OMIM
number 601882) genes have recently been localized to 1p36.2 (Leek et
al, 1997; Hadano et al, 1999), a region commonly deleted in neuro-
blastoma tumours. DFFA is in fact localized in the 1p-deleted SRO
(smallest region of overlap) at 1p36.2-3 deﬁned by our group, and
according to Ohira et al (2000) within a homozygously deleted region
in a neuroblastoma cell line. CASP9 is localized at 1p36.21, approxi-
mately 4 Mb proximal to our SRO-region, but still in the region
commonly deleted by neuroblastoma tumours. In the present study,
we determined the organization of the human gene encoding DFF45,
DFFA, by in-silico cloning. Based on the hypothesis that neuroblas-
tomas are tumours in which mutated cells have abnormalities in
their programmed cell death and the fact that CASP9 and DFFA
are localized in the neuroblastoma tumour-suppressor hot-spot
region (1p36.2-3), the purpose of the present study was to investigate
whether mutated CASP9 or DFFA could be causative in the develop-
ment of neuroblastoma tumours in childhood.
MATERIALS AND METHODS
Patients and controls
DNA was extracted from frozen (7708C) tumour samples
obtained from 44 Scandinavian patients with neuroblastoma of
all different stages (Table 1). Three were stage 1, three were stage
2A, one was stage 2B, 13 were stage 3, two were stage 4S, 17 were
stage 4, and ﬁve were of unknown stages. Clinical data were
derived from Martinsson et al (1995) and from unpublished data.
The neuroblastomas were staged according to the International
Neuroblastoma Staging System criteria (INSS; Brodeur et al,
1993). DNA was also extracted from EDTA-blood obtained from
97 normal control individuals from western Sweden. If a DNA
variation was found in a patient, in general, 47 normal controls
were screened in order to determine the normal allele frequency
of this variant (i.e. 94 alleles). If the polymorphism could not be
found in this set of 47, another set of 50 normal controls were
screened (i.e. in total 194 alleles).
Mapping and BAC (bacterial artiﬁcial chromosome)-contig
construction
CASP9 and DFFA were mapped by running an alignment search
(BLAT-search) of each of the complete coding sequences
(NM_001229 and NM_001229) on ‘Golden path’ at UCSC
(http://genome.ucsc.edu; Figure 1A). BACs were found by screen-
ing a BAC-library (Research Genetics, Huntsville, AL, USA).
Some of the 16 BACs in the present study are from earlier
published results (Ejeskar et al, 2001); while some are new (Figure
1B). BAC-ends were sequenced using Big Dye Terminator chemis-
try (Applied Biosystems, Foster City, CA, USA) and the universal
T7- and SP6-primers. The BAC-contig was constructed by running
alignment searches of seven markers (D1S508, GATA4H04,
D1S214, GGAT3G03, D1S160, D1S503 and D1S244) and all avail-
able BAC-end sequences on ‘Golden path’ at UCSC. The markers
and BACs were then aligned to UCSC-clones (Figure 1B). Marker
D1S244 and the DFFA (exons 1 and 5) and the CORT genes, were
ﬁne-mapped by PCR-assay (data not shown) against four BACs
(318-F24, 513-I12, 347-P23 and 387-I22; Figure 1C). All PCR’s
were run with positive and negative controls, and against two
different colonies from the same BAC.
PCR-ampliﬁcation
Primer sequences for CASP9 and DFFA were selected by means of
the DNASTAR primer select software (LASERGENE, Madison, WI,
USA; data available on request). Primers for CASP9 were
constructed from the nine published exon sequences (Figure 2A)
and the mRNA sequence (GenBank accession numbers:
AB019197 (exon 1); AB019198 (exon 2); AB019199 (exon 3);
AB019200 (exon 4); AB019201 (exon 5); AB019202 (exon 6);
AB019203 (exon 7); AB019204 (exon 8); AB019205 (exon 9);
NM_001229 (mRNA)). The promoter region of the CASP9 gene
could not be investigated, because the CASP9 upstream sequence
was not available. Primers for DFFA exons and promoter were
constructed from the sequence of an unﬁnished chromosome 1
clone (GenBank accession number: AL354956) and from the
mRNA sequence (GeneBank accession number: NM_004401).
Forward (F) and reverse (R) primers were synthesized using an
ABI Applied Biosystem 392 DNA/RNA Synthesizer (Applied
Biosystems) or ordered from Life Technologies (www.invitrogen.-
com; Life Technologies, Inc. Gaitherburg, MD, USA).
Ampliﬁcations were performed according to standard procedures
at our laboratory (for details see Abel et al, 1999) with 30 cycles
of 30–45 s at 958C, 30–45 s at 52–648C (dependent on which
exon) and 60 s at 728C.
DNA-sequencing
Sequencing was performed with an ABI PRISM 377 DNA Sequen-
cer (Applied Biosystems). The sequencing reactions were made
with ABI PRISM Big Dye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems). The PCR-products were puri-
ﬁed with QIAquick Spin PCR puriﬁcation kit (Qiagen, Hilden,
Germany) or the Multiscreen PCR; 96 well puriﬁcation system
(Millipore Corporation, Bedford, MA, USA), and the concentra-
tions of the PCR-products were estimated by comparison to a
100 bp-mass ladder on a 2% agarose gel. The sequence reaction
products were precipitated and diluted according to standard
procedures at our laboratory (for details see Abel et al, 1999).
The samples were denatured for 3 min at 958C on a thermo block,
and loaded on a 7% acryl amide gel.
In-silico cloning of DFFA
The genomic structure of the DFFA gene was determined by in-sili-
co cloning. A BLAT-search of the DFFA complete coding sequence
(GenBank accession number: NM_004401) was performed against
‘unﬁnished htgs’. One of the three hits was the unﬁnished chromo-
some 1 clone with GenBank accession number: AL354956, which
was used to determine the DFFA genomic structure (Figure 3A
and Table 2). To ﬁnd a likely promoter region of DFFA we used
NNPP – Eukaryotic promoter prediction by neural network avail-
able at BCM Search Launcher (URL: http://searchlauncher.
bcm.tmc.edu/seq-search/gene-search.html); the TSSG and the
TSSW-human PolII recognition programs at the same URL were
used to predict the most likely Polymerase II binding site.
Expression analysis
cDNA was extracted and synthesized according to RNasy (Qiagen)
and Superscript II (Promega, Madison, WI, USA) protocols. The
cDNA quality was tested by PCR with GAPD-primers: sense, 5'-
GGGGAGCCAAAAGGGTCATCATCT-3', and antisense, 5'-
GAGGGGCCATCCACAGTCTTCT-3' with 30 standard cycles of
ampliﬁcation (30–45 s at 958C, 30–45 s at 608C and 60 s at
728C). This primer pair spans two introns (intron no. 5 and 6),
and generates a cDNA band at 235 bp and a genomic band at
520 bp. cDNAs showing positive PCR-results for the genomic band
(520 bp) were not included in this study.
The expression of CASP9, its alternatively spliced variant
CASP9S, and the total expression of DFFA were tested by RT–
PCR. The long (encoding DFF45) and the short alternatively
spliced forms (encoding DFF35) of DFFA were not distinguished
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in 50 ml and performed for 30–35 standard cycles of ampliﬁcation
(30–45 s at 958C, 30–45 s at 508C and 60 s at 728C). The results
were analyzed by running 10 ml PCR product on an ethidium
bromide stained 2% agarose gel (Figure 4). All expression results
were checked three times.
RESULTS
Mapping and construction of BAC-contig
According to BLAT-searches in UCSC (http://genome.ucsc.edu),
CASP9 is localized to 1p36.21 and DFFA is localized to 1p36.22 very
near marker D1S244 (Figure 1A). Based on the order of the seven
markers according to UCSC (D1S508, GATA4H04, D1S214,
GGAT3G04, D1S160, D1S503 and D1S244), the SRO of deletions
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Table 1 Summary of clinical parameters and experimental data from
patients with neuroblastoma
Clinical parameters
Patients NB stage 1p-del MYCN 17q gain
156 1 77 7
161 1 77 7
181 1 77 +
133 2A 77 nd
177 2A 7 nd 7
St 156 2A 77 +
127 2B 77 7
128 3 nd nd 7
135 3 nd nd +
136 3 nd nd +
157 3 77 7
187 3 7 nd +
St 99 3 + 7 +
St 100 3 77 7
St 124 3 + 7 +
St 131 3 + + +
St 149 3 + 7 nd
St 158 3 7/+ 7 nd
St 164 3 7/(+) + +
St 208 3 + + nd
125 4S nd nd 7
162 4S 77 nd
32 4 77 +
41 4 77 +
55 4 + + +
95 4 + + +
106 4 + + +
112 4 77 7
114 4 77 (+)
123 4 nd nd +
155 4 + 77
184 4 + + nd
189 4 + + nd
St 102 4 + nd +
St 119 4 + 7 (+)
St 129 4 + + nd
St 153 4 7/+ 7 +
St 172 4 (+)/77 nd
St 190 4 +/77 nd
St 116 4 + + 7
St 142 4 + + +
St 108 ? 77 nd
St 174 ? + + nd
St 196 ? + + nd
Column 1: Sample name; column 2: 1, 2A, 2B, 4S, 3, and 4, neuroblastoma stage; ?,
unknown stage; column 3: +, 1p-deletion; 7, no 1p-deletion; +/7, uncertain result
(based on short tandem repeat polymorphism according to Martinsson et al, 1995
and FISH); column 4: +, MYCN-ampliﬁcation; 7, no MYCN-ampliﬁcation; column
5: +, 17q gain; 7, no 17q gain; (+), uncertain results (according to Abel et al, 1999).
T
a
b
l
e
2
S
e
q
u
e
n
c
e
s
a
t
t
h
e
D
F
F
A
s
p
l
i
c
e
j
u
n
c
t
i
o
n
s
E
x
o
n
P
o
s
i
t
i
o
n
S
p
l
i
c
e
a
c
c
e
p
t
o
r
s
e
q
u
e
n
c
e
L
e
n
g
t
h
S
p
l
i
c
e
d
o
n
o
r
s
e
q
u
e
n
c
e
1
5
0
6
3
1
—
5
0
8
2
2
5
'
-
U
T
R
,
A
T
G
G
A
G
G
T
G
A
C
C
G
G
G
G
A
C
G
C
1
9
2
C
G
A
A
G
A
C
C
T
G
A
G
G
A
G
C
A
A
G
G
G
T
T
G
G
C
T
C
G
G
G
A
C
C
C
C
G
G
G
C
2
5
3
7
1
8
—
5
3
8
7
9
A
A
A
T
A
T
T
T
T
A
T
T
C
T
T
T
T
C
A
G
C
C
T
G
T
G
A
C
A
T
T
C
T
G
G
C
C
A
T
T
1
6
2
A
T
G
G
G
C
A
T
A
C
A
A
C
A
A
T
T
C
A
G
G
T
A
A
G
A
A
A
C
T
C
T
A
G
C
C
A
T
G
T
3
5
5
7
2
4
—
5
5
8
6
6
C
A
T
T
T
T
C
T
C
C
C
A
T
G
T
G
T
C
A
G
A
T
G
G
A
G
G
T
A
C
A
G
C
T
T
G
G
A
T
T
1
4
3
T
A
T
C
A
G
A
G
G
A
G
G
A
C
C
T
C
C
A
G
G
T
A
A
A
G
C
C
T
C
C
T
C
C
A
C
A
A
C
C
4
5
9
4
3
6
—
5
9
6
2
5
C
G
T
C
T
G
T
G
T
T
T
G
T
T
T
G
T
T
A
G
A
T
G
C
T
T
G
T
T
G
A
C
G
C
T
C
C
C
T
G
1
9
0
C
C
T
C
T
T
G
T
C
A
A
A
G
C
A
G
G
A
A
G
G
T
A
G
G
A
C
T
C
T
C
T
G
C
A
G
G
C
A
G
5
a
5
9
8
4
7
—
5
9
9
9
8
G
T
C
T
C
G
T
G
T
C
T
C
C
T
T
T
G
C
A
G
A
G
T
C
C
A
A
A
G
C
T
G
C
C
T
T
T
G
G
T
1
5
2
T
A
T
C
T
A
G
T
C
A
G
G
A
T
T
T
G
G
A
G
G
T
G
G
G
C
G
G
A
A
A
C
C
A
G
G
G
T
C
A
5
b
5
9
8
4
7
—
6
0
0
2
2
G
T
C
T
C
G
T
G
T
C
T
C
C
T
T
T
G
C
A
G
A
G
T
C
C
A
A
A
G
C
T
G
C
C
T
T
T
G
G
T
?
T
A
T
C
T
A
G
T
C
A
G
G
A
T
T
T
G
G
A
G
G
T
G
G
G
C
G
G
A
A
A
C
C
A
G
G
G
T
C
A
C
T
G
A
3
'
-
U
T
R
6
6
1
3
5
4
—
6
2
1
4
7
G
G
T
T
T
T
T
A
T
T
C
T
T
G
C
T
G
C
A
G
T
T
G
G
T
T
A
C
C
A
A
G
G
A
A
G
A
C
C
C
7
9
4
C
C
A
G
A
C
A
G
G
A
T
C
C
C
A
C
A
T
A
G
3
'
-
U
T
R
C
o
l
u
m
n
1
;
D
F
F
A
e
x
o
n
s
;
e
x
o
n
5
i
s
t
h
e
n
o
r
m
a
l
l
y
t
r
a
n
s
c
r
i
b
e
d
e
x
o
n
g
e
n
e
r
a
t
i
n
g
t
h
e
f
u
l
l
l
e
n
g
t
h
D
F
F
A
m
R
N
A
(
e
n
c
o
d
i
n
g
D
F
F
4
5
)
;
e
x
o
n
5
b
i
s
t
h
e
a
l
t
e
r
n
a
t
i
v
e
l
y
s
p
l
i
c
e
d
e
x
o
n
g
e
n
e
r
a
t
i
n
g
t
h
e
s
h
o
r
t
e
r
f
o
r
m
o
f
D
F
F
A
m
R
N
A
(
e
n
c
o
d
i
n
g
D
F
F
3
5
)
;
c
o
l
u
m
n
2
;
B
a
s
e
-
p
a
i
r
p
o
s
i
t
i
o
n
i
n
t
h
e
u
n
ﬁ
n
i
s
h
e
d
c
h
r
o
m
o
s
o
m
e
1
c
l
o
n
e
A
L
3
5
4
9
5
6
,
f
o
u
n
d
b
y
i
n
s
i
l
i
c
o
m
a
p
p
i
n
g
;
c
o
l
u
m
n
3
;
2
0
b
a
s
e
s
o
f
t
h
e
ﬂ
a
n
k
i
n
g
i
n
t
r
o
n
a
n
d
t
h
e
e
x
o
n
s
e
q
u
e
n
c
e
r
e
s
p
e
c
t
i
v
e
l
y
;
e
x
o
n
s
e
q
u
e
n
c
e
s
a
r
e
s
h
o
w
n
i
n
b
o
l
d
a
n
d
t
h
e
i
n
t
r
o
n
s
e
q
u
e
n
c
e
s
a
r
e
s
h
o
w
n
i
n
i
t
a
l
i
c
s
t
y
l
e
;
f
o
r
e
x
o
n
s
1
t
h
e
ﬁ
r
s
t
2
0
b
a
s
e
s
o
f
t
h
e
c
o
d
i
n
g
s
e
q
u
e
n
c
e
i
s
s
h
o
w
n
;
U
T
R
,
U
n
t
r
a
n
s
l
a
t
e
d
r
e
g
i
o
n
;
c
o
l
u
m
n
4
;
E
x
o
n
l
e
n
g
t
h
i
n
b
p
;
?
,
u
n
k
n
o
w
n
l
e
n
g
t
h
;
c
o
l
u
m
n
5
;
2
0
b
a
s
e
s
o
f
t
h
e
ﬂ
a
n
k
i
n
g
i
n
t
r
o
n
a
n
d
t
h
e
e
x
o
n
s
e
q
u
e
n
c
e
r
e
s
p
e
c
t
i
v
e
l
y
;
e
x
o
n
s
e
q
u
e
n
c
e
s
a
r
e
s
h
o
w
n
i
n
b
o
l
d
a
n
d
t
h
e
i
n
t
r
o
n
s
e
q
u
e
n
c
e
s
a
r
e
s
h
o
w
n
i
n
i
t
a
l
i
c
s
t
y
l
e
;
t
h
e
e
x
t
e
n
d
e
d
p
a
r
t
o
f
e
x
o
n
5
b
i
s
s
h
o
w
n
i
n
b
o
l
d
a
n
d
i
s
u
n
d
e
r
l
i
n
e
d
;
f
o
r
e
x
o
n
s
6
t
h
e
l
a
s
t
2
0
b
a
s
e
s
o
f
t
h
e
c
o
d
i
n
g
s
e
q
u
e
n
c
e
i
s
s
h
o
w
n
;
U
T
R
,
U
n
t
r
a
n
s
l
a
t
e
d
r
e
g
i
o
n
.
Analyses of CASP9 and DFFA in human neuroblastoma
F Abel et al
598
British Journal of Cancer (2002) 86(4), 596–604 ã 2002 Cancer Research UKthat our group had previously deﬁned (D1S508, D1S244, Ejeskar et
al, 2001) is now localized proximal to marker D1S214 and distal to
marker D1S244 (Figure 1B). Fifteen of the 16 BACs included in this
study reside in this region. According to distances in the UCSC brow-
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Chr. Band
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A
B
C
D
DFFA CASP9
Markers
Chr. Band
Base position
Gap position
Clone coverage
BAC-contig
Golden path,
UCSC, 2001
UBE4B/HDNB1/UFD2 KIAA0591F/KIF1B-b CORT PEX14
PGD DFFA
D1S244
Ohira et al, 2000
PEX14
KIAA0591F/KIF1B-b UBE4B/HDNB1/UFD2 DFFA
Figure 1 Schematic representation of the localization of CASP9 and DFFA based on alignment-search (‘BLAT-research’) data from ‘Golden path’ at
UCSC (http://genome.ucsc.edu). (A) Chromosome band 1p36.13-33 corresponding to approximately 15 Mb, with base position according to UCSC.
CASP9 is localized to 1p36.21, and DFFA is localized to 1p36.22. (B) Clone coverage at chromosome band 1p36.22-31 corresponding to approximately
5 Mb. Gap positions in the UCSC-contig are shown at the top. Grey boxes represent clones from ‘Golden path’. Black horizontal bars represent BAC-clones
found by our group by PCR-based screening of a BAC-library (Research Genetics). BACs are located according to alignment of BAC-ends to UCSC-clones
(dotted vertical lines), and their content of polymorphic markers (black vertical lines). The shaded area represents the SRO of deletions deﬁned earlier by
our group (Ejeskar et al, 2001). The dotted area and the thick black bar in the right corner represent the homozygously deleted region found by Ohira et al
(2000) that partially overlaps the shaded SRO-region. (C) Enlarged view of the homozygously deleted region found by Ohira et al (2000). Grey boxes
represent two clones from ‘Golden path’ (UCSC). BACs are ordered according to alignment of BAC-ends and markers to UCSC-clones (dotted vertical
lines). T7 and SP6 display the two BAC-ends sequenced with the T7- and SP6-universal primers. Arrowheads represent BAC-ends ending up in UCSC gap
positions, or BAC-ends with no available sequence for alignment-search (see text for details). Markers D1S244, and WI-6175 (*) and the genes DFFA and
CORT (*) are mapped to the BACs by PCR assay (black vertical lines). Filled and white ﬁgures represent positive and negative PCR-results, respectively.
(D) Schematic representation of the order of known genes believed to reside in the region by marker D1S244, proposed by ‘Golden path’ at UCSC
(http://genome.ucsc.edu) and Ohira et al (2000).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(4), 596–604ser the SRO-region is approximately 3.5 Mb, and it partially overlaps
the 500 kb homozygously deleted region deﬁned by Ohira et al
(2000). Four of the 16 BACs (318-F24, 513-I12, 347-P23 and 387-
I22) reside in the overlapping region (Figure 1C,D). The sequence
of the SP6-end from BAC 347-P23 was not determined, and could
therefore not be aligned to the UCSC-contig. Both the T7-end from
BAC 387-I22, and the SP6-end from BAC 318-F24 were found to
reside in gap positions of the UCSC-contig. BAC 513-I12, and 347-
P23 gave positive PCR-results for both DFFA and CORT. All four
BACs gave positive PCR-results for marker WI-6175. Only BAC
347-P23 gave positive PCR-results for D1S244, which suggests that
DFFA is localized distal to D1S244 (Figure 1C).
CASP9 studies – detection and analysis of polymorphisms
By sequence analysis we detected four different polymorphisms in
the CASP9 gene in neuroblastoma primary tumours. One was in
the intron upstream of CASP9 exon 2 (IVS1-36G4A; GeneBank
accession number: NM_001229) and the other three were in the
exons. Of the polymorphisms in the coding region, two caused
amino acid residue substitutions (305C4T and 662A4G) and
the third was a silent mutation (408T4C). The 305C4T poly-
morphism in exon 2 caused substitution of codon 102 from a
threonine to isoleucine (ACC?ATC) and we detected it as hetero-
zygous (C/T) in three neuroblastoma patients (cases 156, St100 and
St172) and as homozygous (T/T) in one patient (case 136, Figure
2B). The three patients detected to be heterozygous also displayed
this polymorphism in their corresponding constitutional DNA. In
addition, two of the 47 normal controls were heterozygous for this
polymorphism (Table 3). The 662A4G polymorphism in CASP9
exon 5 caused a substitution of codon 221 from a glutamine to
arginine (CAG?CGG); we found it to occur frequently.
All 44 tumours showed linkage disequilibrium for polymorph-
isms IVS1-36G4A, 408T4C and 662A4G. The two strict
haplotypes seen were (1) A-C-G and (2) G-T-A. Of the 44
tumours, 12 were homozygous for haplotype 1; 14, of which three
were informative hemizygous, were homozygous for haplotype 2;
and 18 were heterozygous. Of the 48 normal controls 13 were
homozygous for haplotype 1; 12 were homozygous for haplotype
2; and 23 were heterozygous (Table 3).
CASP9 studies - expression analysis
CASP9 was expressed in all neuroblastoma stages (Figure 4). A
slightly weaker expression could be seen in high-stage tumours
(stage 3 and 4). CASP9 was strongly expressed in the ganglioneur-
oma, both tumours of stage 1, and both stage 4S tumours. Four
out of ﬁve stage 3 tumours showed CASP9 expression. Ten out
of 14 stage 4 tumours showed CASP9 expression; four of them
(case 126, 106, St129, and St130B) showed a strong expression,
while the other three were very weak. The expression of the alter-
natively spliced form, CASP9S, in general showed the same
expression pattern as CASP9 (data not shown).
DFFA studies – genomic structure of DFFA
The genomic structure of the DFFA gene was determined by in-
silico cloning from an unﬁnished chromosome 1 clone
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Figure 2 Schematic representation of the CASP9 gene. (A) Exon-intron organization of the gene corresponding to approximately 5 kb from (Hadano et
al, 1999). Exons are numbered from 1–9 in the 5'-3' direction. Light shaded boxes represent the coding regions of each exon. Dark shaded boxes represent
the 5'- and 3'-untranslated ﬂanking regions (UTR’s). The black bars represent the nine ampliﬁed fragments. The dotted line represents the alternatively
spliced CASP9S. (B) Rare polymorphism detected in CASP9. The 305C4T polymorphism located in CASP9 exon 2. Upper panel: Ampliﬁed tumour-
DNA from case 136, homozygous T/T or hemizygous -/T. Lower panel: Ampliﬁed normal-DNA from control Q309, homozygous C/C. (C) The amino
acid sequence of caspase-9 and caspase-9S (GenBank accession numbers: NM_001229 and AF110376 respectively). The caspase-9S sequence is repre-
sented in italics. The consensus Akt phosphorylation motif RRRFSS (Cardone et al, 1998) and the conserved active site pentapeptide QACGG are under-
lined. The arrow denotes the aspartic acid (D) residue after which the cleavage occurs during caspase-9 activation (Srinivasula et al, 1996). Letters coloured
red represent the conserved hydrophobic residues of the
1CARD
97 domain (Hofmann et al, 1997; Zhou et al, 1999). The bold and circled residues indicate
the polymorphic sites where amino acid substitution takes place. Threonine (T) is exchanged for isoleucine (I), caused by the 305C4T base pair substitution.
Arginine (R) is exchanged for glutamine (Q), caused by the 662A4G base-pair substitution.
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British Journal of Cancer (2002) 86(4), 596–604 ã 2002 Cancer Research UK(GenBank accession number: AL354956; Table 2). DFFA is orga-
nized as 6 exons (ﬁve smaller and one large) over a genomic
stretch of approximately 11 kb (Figure 3A). The length of
intron no. 1 could not be determined due to a gap of unknown
size in the clone. No splicing of intron 5 generates the alterna-
tively spliced form, encoding DFF35. The mRNA generated by
this isoform contains normal exons 1 to 4, and a 24 bp-
extended exon 5 (exon 5b, Table 2). Two different promoter
sites were predicted for the forward strand of the DFFA promo-
ter sequence (NNPP – Eucaroyotic promoter prediction by
neural network; LMNL): the ﬁrst between 7249 to 7198 from
the DFFA transcription start point, and the second between 721
to +29 from the DFFA transcription start point. Use of the
TSSG and TSSW-human PolII recognition programs did not
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Figure 3 Schematic representation of the DFFA gene. (A) Exon-intron organization of the gene corresponding to approximately 11 kb. Exons are num-
bered from 1–6 in the 5'-3' direction. Light shaded boxes represent the coding regions of each exon. Dark shaded boxes represent the 5'- and 3'-untrans-
lated ﬂanking regions (UTR’s). The 5' UTR is 56 bp and the most 3' UTR is 581 bp long. The 3' UTR of the alternatively spliced fragment after exon 5 is of
unknown size. The start and stop codons are indicated by arrows. The black bars represent the eight ampliﬁed fragments (promoter-region, exon 1, 2, 3, 4,
5, 6:1 and 6:2). The dotted line represents the normal splicing of DFFA, encoding DFF45. (B) Rare polymorphism detected in DFFA. The 206T4C poly-
morphism located in DFFA exon 2. Upper panel: Ampliﬁed tumour-DNA from case 184, hemizygous -/C. Middle panel: Ampliﬁed constitutional DNA from
case 184 (extracted from blood), heterozygous T/C. Lower panel: Ampliﬁed constitutional DNA from control Q170 (from blood), homozygous T/T. (C)
Ampliﬁed tumour-cDNA from case St 108, heterozygous T/C. (D) The amino acid sequence of DFF45 (GenBank accession number: NP_004392). The
upper sequence represents the DFF45 (331 aa) amino acid sequence, and the lower sequence represents the DFF35 (268 aa) amino acid sequence.
The arrows denote the aspartic acid (D) residue after which the caspase-3 cleavage occurs (Liu et al, 1997; Sakahira et al, 1998). Letters coloured red
(residues 12–100) represent the conserved N-terminal domain; CIDE (Cell-death Inducing DFF45-like Effecter; Zhou et al, 2001). The bold and circled
residue indicates the polymorphic site where the amino acid substitution takes place. Isoleucine (I) is exchanged for threonine (T), caused by the
206T4C base pair substitution.
CASP9
DFFA
GAPDH
Stage: GN 14 S 3 4 +
Figure 4 RT–PCR expression analysis of CASP9 and DFFA from all stages of neuroblastoma. GN, ganglioneuroma; 1, 2B, 3, and 4, stages of neuroblas-
toma; +, positive control. Upper panel: Tumour extracted cDNA ampliﬁed by RT–PCR with CASP9-primers. Middle panel: Tumour extracted cDNA am-
pliﬁed by RT–PCR with DFFA-primers. Lower panel: GAPDH control cDNA ampliﬁed by RT–PCR with GAPDH primers (see text). From left to right:
GN, case St 151; stage 1, 118, 161; stage 4S, 125, 162; stage 3, 157, 187, St 124, St 131, St 149; stage 4, 32, 114, 126, 168, 169, 111, St 153, 95, 106, 155,
174, St 102, St 129, St 130; positive control, St 64.
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sequence.
DFFA studies – detection and analysis of polymorphisms
In DFFA, three different polymorphisms were detected by sequence
analysis: one in the promoter region (IVS0-466T4C; GenBank
accession number: NM 004401). One out of 44 tumours was
homozygous (C/C) for the rare variant of this polymorphism,
and six out of 44 were heterozygous (T/C). Eight out of 47 normal
controls were heterozygous (T/C) for this polymorphism, and none
could be detected that carried the rare homozygous form (C/C;
Table 3). Another polymorphism, which occurred very frequently,
was detected downstream of the coding region of exon 2
(IVS2+40A4G). The third was detected in the coding region of
exon 2 (206 T4C) where it caused an amino acid substitution
of codon 69 from a non-polar to a polar amino acid (Isoleucine
to Threonine). This variant was detected in only two out of 44
tumour samples; case 184 was hemizygous -/C (Table 1; Figure
3B), and case St108 was heterozygous (T/C). RT–PCR based
sequence analysis of the cDNA from case St108 revealed that both
alleles (T and C) were expressed in the tumour (Figure 3C; primers
are available on request). In 97 normal controls (i.e. 194 chromo-
somes), the C variant could only be detected in one sample as
heterozygous (T/C), while 193 alleles were T (Table 3).
DFFA studies – expression analysis
DFFA was expressed in all neuroblastoma stages (Figure 4), with a
noteworthy difference between low-stage and high-stage tumours.
It was expressed in the ganglioneuroma, in both stage 1 tumours,
and in both stage 4S tumours. Four out of the ﬁve stage 3 tumours
showed DFFA expression, but cases 157 and 187 were slightly
weaker. Six out of the 14 stage 4 tumours showed DFFA expres-
sion. Four stage 4 tumours (cases 111, 106, St102 and St130B)
showed a normal expression level, while the other two were very
weak (cases 126, St153B).
DISCUSSION
The heterozygous 1p-deleted SRO in neuroblastoma had already
been deﬁned both by our group (Martinsson et al, 1995; Ejeskar
et al, 2001) and by others (Takeda et al, 1994; Caron et al, 1995;
White et al, 1995; Hogarty et al, 2000). In the present study, we
discuss an update contig of our SRO region that based on align-
ment searches using ‘Golden path’ at UCSC (http://
genome.ucsc.edu; Figure 1B). The 500 kb homozygously deleted
region on 1p36.2 in a neuroblastoma cell line (Ohira et al, 2000)
partially overlaps our SRO (Figure 1B,C). A number of suggested
but also rejected candidate tumour suppressor genes have been
investigated (Maris et al, 1997; Martinsson et al, 1997; Grenet et
al, 1998; Ejeskar et al, 1999, 2000). We have previously analyzed
in detail one of the genes believed to reside in our SRO-region,
and in the region deﬁned by Ohira et al (2000), i.e. CORT (Ejeskar
et al, 2000) without ﬁnding evidence of any role in neuroblastoma
tumorigenesis (Figure 1C). In the present study we have examined
two other genes in neuroblastoma primary tumours, CASP9 and
DFFA. Caspase-9 has been shown to be a key effector of the apop-
totic pathway in the nervous system (Hakem et al, 1998; Kuida et
al, 1998) and DFF45 (encoded by DFFA) an important regulatory
subunit of the DNA fragmentation factor involved in apoptosis.
Both genes (CASP9 and DFFA) have been localized to 1p36.2 (Leek
et al, 1997; Hadano et al, 1999; Figure 1A).
Like CORT, DFFA is believed to be localized both to our SRO-
region (D1S214-D1S244) and the region deﬁned by Ohira et al,
2000; Ejeskar et al, 2001; Figure 1C,D. However, since DFFA maps
very close to marker D1S244, it was uncertain whether the gene is
localized distal or proximal to this marker. PCR-assay against BACs
mapped to the region of UCSC suggests that it is distal and there-
fore resides in our SRO-region (Figure 1C). This suggestion would
accord with the proposed gene order in this region as suggested by
both UCSC (http://genome.ucsc.edu) and Ohira et al (2000)
(Figure 1D).
Forty-four neuroblastoma primary tumours were analyzed by
sequence analysis for mutations in the coding region of the CASP9
and DFFA genes, and in the promoter region of DFFA. In CASP9,
we found two polymorphisms causing amino acid substitutions
(305C4T and 662A4G). The ﬁrst was rare and caused a polar
(threonine) to a non-polar (isoleucine) substitution, with only
three out of 44 heterozygous and one out of 44 homozygous (T/
T; see Figure 2A). The three heterozygous individuals also showed
this polymorphism in their constitutional normal DNA. In the
homozygous patient (case 136), the constitutional normal DNA
was not available and CASP9-LOH could not be determined. This
case 136 could therefore be hemizygous (-/T) for this polymorph-
ism. We found that the 305C4T polymorphism had the same
frequency (4%) in normal controls, but only in the heterozygous
form.
There are several conserved regulatory motifs in caspase-9
(Figure 2C). Its large subunit contains the conserved active site
pentapeptide site QACGG (Srinivasula et al, 1996, 1998). The
312PEPDA
316-site in its amino acid sequence has been shown
to be important for granzyme B cleavage (Srinivasula et al,
1996). Caspase-9 and Apaf-1 bind to each other via their
respective NH2-terminal CED-3 (‘C. elegans Death protein
homologue’) homologous domains in the presence of cyto-
chrome c and dATP; they have been shown to contain a
caspase recruitment domain (CARD) motif that contains several
conserved hydrophobic residues (Hofmann et al, 1997; Zhou et
al, 1999). Moreover, caspase-9 is negatively regulated by phos-
phorylation of the Ser-196 residue at the consensus motif
‘RRRFSS’ (Cardone et al, 1998; Figure 2C). No polymorphism
found in this study could be shown to reside in any of these
regulatory sites, but polymorphisms IVS-36G/A, 408T/C and
662A/G, clearly exhibited two different strict haplotypes; both
were detected in approximately the same frequency in patients
and normal controls, and none of the samples analyzed
diverged from this pattern. Using RT–PCR, we found that
caspase-9 and caspase-9S exhibited the same expression pattern,
but that the expression in high stage tumours was slightly lower
for both isoforms (Figure 4).
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Table 3 Allele frequences detected in CASP9 and DFFA
Detected
Allele frequency
Gene Exon polymorphism Patients Normals Effect
CASP9 1 none
2 IVS1-36G4A 42/88 49/94 non-coding
305C4T 5/88 2/96 Thr-4Ile
408T4C 42/88 49/94 silent
3 none
4 none
5 662A4G 42/88 49/94 Gln-4Arg
6 none
7 none
8 none
9 none
DFFA Prom IVS0-466T4C 8/88 8/94 non-coding
1 none
2 IVS2+40A4G 43/88 106/194 non-coding
206T4C 3/88 1/194 Ile-4Thr
3 none
4 none
5 none
6 none
Rare allele variants are shown in bold.
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DFFA gene. The gene is organized as six exons (Table 2 and Figure
3A), which is the same as that of the murine ICAD gene (Kawane
et al, 1999). Other similarities are the alternatively spliced isoforms
encoding murine ICAD-S or human DFF35, which are both gener-
ated by no splicing of intron 5. In DFFA we found one
polymorphism in the promoter-region in ﬁve of 44 patients
(IVS0-466T4C). One stage 3 neuroblastoma tumour (St158) was
homozygous for the rare allele (C); eight of 47 normal controls
displayed this polymorphism, but only in the heterozygous form
(T/C). This polymorphism is located only nine bases downstream
of a predicted TFIID-binding site (-TATATTTATTTAA-; as
suggested by TESS-search for transcription factor binding sites).
In exon 2 of DFFA, two of 44 patients displayed one rare poly-
morphism in the coding region (206 T4C) that caused an amino
acid substitution of codon 69 from a non-polar to a polar amino
acid (Isoleucine to Threonine; Figure 3D). Case 184 was hemizy-
gous -/C (Table 1 and Figure 3B), due to deletion, and case
St108 was heterozygous (T/C). The constitutional DNA of both
these two patients was heterozygous (T/C) for this polymorphism
in. Only one of 97 normal controls (1%) showed this polymorph-
ism in the heterozygous form, compared to two out of 44 of the
neuroblastoma patients (4%; Table 3). Strikingly, the normal allele
(T) was deleted in case 184 while only the rare C allele was retained
in the tumour. However, RT–PCR based sequence analysis of the
cDNA from case St108 revealed that both alleles (T and C) were
expressed in this tumour (Figure 3C). DFF45 is a protein that
comprises 331 amino acids (Figure 3D). In the short isoform,
DFF35, the ﬁrst 261 amino acids are identical. Both DFF45 and
DFF35 carry two caspase-3-recognition sites (amino-acid positions
117 and 224; Sakahira et al, 1998; Gu et al, 1999). As only the full-
length DFF45 functions as a chaperone for DFF40 (Sakahira et al,
2000), amino acids 261 to 331 seem relevant to this function (Gu
et al, 1999). Zhou et al (2001) have recently reported that the N-
terminal domain (NTD) of DFF45 (residues 12–100) is homolo-
gous to the NTD of DFF40. Moreover, the NTD of DFF45 is
alone unstructured in solution, and its folding is induced upon
binding to DFF40 NTD. Therefore, deletion of NTD from either
DFF40 or DFF45 results in the production of an inactivate nucle-
ase. Interestingly, the preserved convex hydrophobic patch of
DFF40 forms van der Waal contact with the preserved concave
hydrophobic patch of DFF45, through interaction between Ala-
22/Tyr-75, Val-21/Val-70, and Phe-19/Ile-69 from DFF40 and
DFF45, respectively (Zhou et al, 2001). The 206 T4C mutation/
polymorphism variant causing a substitution of Ile-69, found in
this study, could therefore disturb the hydrophobic contact
between the NTD’s. If it does, no active nucleases would be
produced during apoptosis in the homozygous mutant/poly-
morphic cells. In the present study, we also investigated the
expression of DFFA in neuroblastoma tumours (Figure 4). We
selected primers of which both the normal and the alternatively
spliced variant were ampliﬁed by the same PCR reaction. We
detected expression of DFFA in tumours of all different stages,
but found a noteworthy difference between that in low-stage and
high-stage tumours. It was not or very poorly expressed in stages
3 and 4, which accords with an earlier study (Ohira et al, 2000).
We would conclude by suggesting that caspase-9, and, in parti-
cular, DFF45 are good candidates for the supposed tumour
suppressor on 1p36.2-3. Firstly, the biology of these genes that
are key players of the apoptotic signalling system renders them
attractive as neuroblastoma candidate genes. Secondly, they both
map to the consensus region deleted in all neuroblastoma cases
with 1p deletion while DFFA also maps within the 500 kb region
of homozygous loss in a neuroblastoma cell line characterized by
Ohira et al (2000). Thirdly, we detected in two neuroblastoma
cases an interesting variant polymorphism in DFFA that in one
case retained as the sole allele in a tumour where the common
allele had been lost by deletion. This allele variant was present only
in one normal allele out of the 194 that we tested. Fourthly, low-
stage tumours expressed the two genes much more distinctly than
did the high-stage tumours. This was especially pronounced for
DFFA: its expression in high-stage tumours was very low or absent.
We would therefore suggest that, at present, neither gene be ruled
out as a candidate for a neuroblastoma tumour suppressor gene.
We hope that this conclusion will prompt others to study these
genes, in particular DFFA, in their neuroblastoma tumour material.
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